Daratumumab is a human immunoglobulin (Ig)Gκ monoclonal antibody targeting CD38 with direct on-tumor1–4 and immunomodulatory5–7 mechanisms of action that has demonstrated overall survival benefit in three frontline regimens8–10 and was the first anti-CD38 monoclonal antibody approved in newly diagnosed multiple myeloma (NDMM)11,12. This evidence concerns the gene CD38 and plasma cell myeloma.